Items where Author is "Mills, Mackenzie"

Augustovski, Federico, Colaci, Carla, Mills, Mackenzie, Chávez, Danitza, Argento, Fernando, Alfie, Verónica, Pichon Riviere, Andrés, Kanavos, Panos ORCID: 0000-0001-9518-3089 and Alcaraz, Andrea (2024) A systematic review of value criteria for next-generation sequencing/ comprehensive genomic profiling to inform value framework development. Value in Health, 27 (5). 670 - 685. ISSN 1098-3015

Kanavos, Panos ORCID: 0000-0001-9518-3089, Alcaraz, OA, Chávez, Danitza, Colaci, C, Haig, Madeleine, Argento, F, Main, Caitlin, Alfie, Verónica, Mills, Mackenzie, Pichon-Riviere, DA and Augustovski, F (2023) HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe: building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Value in Health, 26 (12). S355 - S355. ISSN 1098-3015

Politopoulou, Konstantina, Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2023) HTA255 First-in-class drugs in HTA: blunder or bliss? Value in Health, 26 (12). S369 - S369. ISSN 1098-3015

Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2023) Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products: evidence from nine OECD countries. PharmacoEconomics - Open, 7 (4). 553 - 565. ISSN 2509-4262

Mills, Mackenzie (2023) HTA barriers for conditional approval drugs. PharmacoEconomics, 41 (5). 529 - 545. ISSN 1170-7690

Mills, Mackenzie, Michaeli, Daniel, Miracolo, Aurelio and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2023) Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Services Research, 23 (1). p. 150. ISSN 1472-6963

Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2022) How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Health Policy, 126 (11). 1130 - 1143. ISSN 0168-8510

Michaeli, Daniel Tobias, Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2022) Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Applied Health Economics and Health Policy, 20 (5). 757 - 768. ISSN 1175-5652

Michaeli, Daniel Tobias, Mills, Mackenzie, Michaeli, Thomas, Miracolo, Aurelio and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2022) Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational New Drugs, 40 (4). 798 - 809. ISSN 0167-6997

Miracolo, Aurelio, Sophiea, Marisa, Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2021) Sin taxes and their effect on consumption, revenue generation and health improvement: a systematic literature review in Latin America. Health Policy and Planning, 36 (5). 790 - 810. ISSN 0268-1080

Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2020) Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy, 124 (3). pp. 239-251. ISSN 0168-8510

Kanavos, Panos ORCID: 0000-0001-9518-3089, Mills, Mackenzie and Zhang, Anwen (2019) Pharmaceutical policy in China. . LSE Consulting, London, UK.

Kanavos, Panos ORCID: 0000-0001-9518-3089, Mills, Mackenzie, Cheatley, Jane, Lopez-Casasnovas, Guillem, Manganelli, Anton, Maynou, Laia and Serra, Miquel (2017) Controlling expenditure within the Spanish pharmaceutical market: macro- and micro-level policy approaches. . LSE Health, London, UK.